This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dekairelle, A.-F. Articles by Gala, J.-L. Search for Related Content PubMed PubMed Citation Articles by Dekairelle, A.-F. Articles by Gala, J.-L.

Assessment of the Transcriptional Activity of p53 Improves the Prediction of Recurrence in Superficial Transitional Cell Carcinoma of the Bladder

Authors' Affiliations: ¹ Laboratory of Applied Molecular Technologies, Center for Human Genetics and ² Laboratory of Cellular Physiology, Université catholique de Louvain; ³ Division of Urology and ⁴ Department of Pathology, Cliniques Universitaires Saint-Luc; and ⁵ Defense Laboratories Department, Belgian Armed Forces, Brussels, Belgium

Requests for reprints: Jean-Luc Gala, Laboratory of Applied Molecular Technologies, Center for Human Genetics, Université catholique de Louvain, Clos Chapelle-aux-Champs, 30-UCL/30.46, B-1200 Brussels, Belgium. Phone: 32-2-764-3165; Fax: 32-2-764-3166; E-mail: gala{at}lbcm.ucl.ac.be.

Purpose: To investigate the value of p53 functional analysis of separated alleles in yeast (FASAY) as a witness of p53/p21 pathway alteration and as a predictor of recurrence in superficial transitional cell carcinomas.

Experimental Design: p53 transcriptional activity was prospectively analyzed in 52 newly diagnosed transitional cell carcinoma using FASAY competent for the transactivation of p21 and bax promoters. TP53 and p21 gene expression was quantified by real-time PCR, and expression of corresponding proteins was assessed by immunohistochemistry. In addition to tumor stage and grade, the predictive value of FASAY, real-time PCR, and immunohistochemistry for tumor recurrence was assessed by Cox survival analysis.

Results: A total (p21 and bax) or partial (bax only) loss of transcriptional activity was observed in 15 of 52 (29%) and 4 of 52 (7.7%) cases, respectively, a partial loss being consistently associated with R283H mutation. p53 nuclear overexpression grossly overestimated (40%) or underestimated (10%) the true incidence of p53 transcriptional abnormalities, especially in T_a-T₁ grade 1 to 2 tumors. Loss of p21 transactivation significantly correlated with decreased p21 gene expression and lack of expression of p21 (P = 0.001). FASAY had a better predictive value for recurrence than p53 immunohistochemistry (Cox hazard ratio, 6.57 versus 3.95; P = 0.0002 versus 0.019, respectively), whereas neither p21 immunohistochemistry (hazard ratio, 1.9; P = 0.29) nor TP53 or p21 gene expression were significant predictors of recurrence. The prognostic difference between FASAY and p53 immunohistochemistry was maintained in the subgroup of T_a-T₁ grade 3 tumors.

Conclusions: FASAY is a valuable surrogate marker for assessing p53/p21 pathway alteration and predicts transitional cell carcinoma recurrence better than p53 immunohistochemistry.

This article has been cited by other articles:

				L. M. Irenge, A. Robert, and J.-L. Gala Quantitative Assessment of Human {beta}-Globin Gene Expression In Vitro by TaqMan Real-Time Reverse Transcription-PCR: Comparison with Competitive Reverse Transcription-PCR and Application to Mutations or Deletions in Noncoding Regions Clin. Chem., December 1, 2005; 51(12): 2395 - 2396. [Full Text] [PDF]